DK2536746T3 - Disulphide-bond stabilized functional soluble MHC class II heterodimeric - Google Patents
Disulphide-bond stabilized functional soluble MHC class II heterodimeric Download PDFInfo
- Publication number
- DK2536746T3 DK2536746T3 DK11730044.2T DK11730044T DK2536746T3 DK 2536746 T3 DK2536746 T3 DK 2536746T3 DK 11730044 T DK11730044 T DK 11730044T DK 2536746 T3 DK2536746 T3 DK 2536746T3
- Authority
- DK
- Denmark
- Prior art keywords
- mhc class
- molecule
- molecules
- chain
- recombinant
- Prior art date
Links
- 108091054438 MHC class II family Proteins 0.000 title claims description 204
- 102000043131 MHC class II family Human genes 0.000 title claims description 203
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 143
- 238000000034 method Methods 0.000 claims description 84
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 82
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims description 76
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims description 75
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 64
- 230000027455 binding Effects 0.000 claims description 50
- 108091008874 T cell receptors Proteins 0.000 claims description 39
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 39
- 230000004927 fusion Effects 0.000 claims description 36
- 238000010186 staining Methods 0.000 claims description 32
- 201000010099 disease Diseases 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 241001529936 Murinae Species 0.000 claims description 23
- 230000001580 bacterial effect Effects 0.000 claims description 18
- 235000018417 cysteine Nutrition 0.000 claims description 17
- 230000000890 antigenic effect Effects 0.000 claims description 16
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 15
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 15
- 241000724791 Filamentous phage Species 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 108060003951 Immunoglobulin Proteins 0.000 claims description 11
- 102000018358 immunoglobulin Human genes 0.000 claims description 11
- 230000000087 stabilizing effect Effects 0.000 claims description 11
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 9
- 102000018697 Membrane Proteins Human genes 0.000 claims description 5
- 108010052285 Membrane Proteins Proteins 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 208000031513 cyst Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 81
- 102000004196 processed proteins & peptides Human genes 0.000 description 63
- 108090000623 proteins and genes Proteins 0.000 description 58
- 238000004519 manufacturing process Methods 0.000 description 41
- 235000018102 proteins Nutrition 0.000 description 41
- 102000004169 proteins and genes Human genes 0.000 description 41
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 35
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 35
- 230000014509 gene expression Effects 0.000 description 27
- 238000002823 phage display Methods 0.000 description 27
- 230000035772 mutation Effects 0.000 description 26
- 239000013604 expression vector Substances 0.000 description 23
- 150000007523 nucleic acids Chemical class 0.000 description 22
- 239000012528 membrane Substances 0.000 description 21
- 239000006187 pill Substances 0.000 description 20
- 108020004707 nucleic acids Proteins 0.000 description 19
- 102000039446 nucleic acids Human genes 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 17
- 239000013598 vector Substances 0.000 description 17
- 108010076504 Protein Sorting Signals Proteins 0.000 description 16
- 238000013459 approach Methods 0.000 description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 14
- 238000005516 engineering process Methods 0.000 description 13
- 125000000539 amino acid group Chemical group 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 238000000684 flow cytometry Methods 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 239000000833 heterodimer Substances 0.000 description 12
- 210000002845 virion Anatomy 0.000 description 12
- 102000043129 MHC class I family Human genes 0.000 description 11
- 108091054437 MHC class I family Proteins 0.000 description 11
- 238000006471 dimerization reaction Methods 0.000 description 11
- 210000003000 inclusion body Anatomy 0.000 description 11
- 230000003993 interaction Effects 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 241000894007 species Species 0.000 description 10
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 9
- 239000012636 effector Substances 0.000 description 9
- 102000037865 fusion proteins Human genes 0.000 description 9
- 108020001507 fusion proteins Proteins 0.000 description 9
- 101710132601 Capsid protein Proteins 0.000 description 8
- 101710094648 Coat protein Proteins 0.000 description 8
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 8
- 101710125418 Major capsid protein Proteins 0.000 description 8
- 101710141454 Nucleoprotein Proteins 0.000 description 8
- 101710083689 Probable capsid protein Proteins 0.000 description 8
- 150000001945 cysteines Chemical class 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 241000238631 Hexapoda Species 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 229960002685 biotin Drugs 0.000 description 7
- 235000020958 biotin Nutrition 0.000 description 7
- 239000011616 biotin Substances 0.000 description 7
- 230000001086 cytosolic effect Effects 0.000 description 7
- 210000002443 helper t lymphocyte Anatomy 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 210000001322 periplasm Anatomy 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 108700028369 Alleles Proteins 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 108010010378 HLA-DP Antigens Proteins 0.000 description 6
- 102000015789 HLA-DP Antigens Human genes 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 210000003527 eukaryotic cell Anatomy 0.000 description 6
- 239000002955 immunomodulating agent Substances 0.000 description 6
- 229940121354 immunomodulator Drugs 0.000 description 6
- 125000006850 spacer group Chemical group 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 108010058597 HLA-DR Antigens Proteins 0.000 description 5
- 102000006354 HLA-DR Antigens Human genes 0.000 description 5
- 108010046732 HLA-DR4 Antigen Proteins 0.000 description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- 108010090804 Streptavidin Proteins 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 102000005720 Glutathione transferase Human genes 0.000 description 4
- 108010070675 Glutathione transferase Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 101710154606 Hemagglutinin Proteins 0.000 description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 101710176177 Protein A56 Proteins 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000185 hemagglutinin Substances 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000009465 prokaryotic expression Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 102220075834 rs369735050 Human genes 0.000 description 4
- 238000002741 site-directed mutagenesis Methods 0.000 description 4
- 230000034005 thiol-disulfide exchange Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 108090000565 Capsid Proteins Proteins 0.000 description 3
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- 208000015943 Coeliac disease Diseases 0.000 description 3
- 102100036243 HLA class II histocompatibility antigen, DQ alpha 1 chain Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 206010043376 Tetanus Diseases 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000007876 drug discovery Methods 0.000 description 3
- 238000000126 in silico method Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 102220277622 rs550945533 Human genes 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- 240000005528 Arctium lappa Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- -1 FkpA Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010022741 HLA-DPw1 antigen Proteins 0.000 description 2
- 101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 description 2
- 101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 description 2
- 101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 description 2
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101100533690 Pasteurella multocida (strain Pm70) slyD gene Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 2
- 102100040160 Rabankyrin-5 Human genes 0.000 description 2
- 101710086049 Rabankyrin-5 Proteins 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000006229 amino acid addition Effects 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 229960002713 calcium chloride Drugs 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 101150027203 fkpA gene Proteins 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000000302 molecular modelling Methods 0.000 description 2
- 238000002887 multiple sequence alignment Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 238000005580 one pot reaction Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000012128 staining reagent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- RDEIXVOBVLKYNT-HDZPSJEVSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-[(1r)-1-aminoethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2 Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)[C@@H](C)N)N)[C@@H](N)C[C@H]1N.O1[C@H]([C@@H](C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-HDZPSJEVSA-N 0.000 description 1
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 1
- XNKICCFGYSXSAI-UHFFFAOYSA-N 1,1-diphenylpropan-2-amine Chemical compound C=1C=CC=CC=1C(C(N)C)C1=CC=CC=C1 XNKICCFGYSXSAI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QKCKCXFWENOGER-UHFFFAOYSA-N 2-phenyloxazol-5(4H)-one Chemical compound O1C(=O)CN=C1C1=CC=CC=C1 QKCKCXFWENOGER-UHFFFAOYSA-N 0.000 description 1
- QXZBMSIDSOZZHK-DOPDSADYSA-N 31362-50-2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CNC=N1 QXZBMSIDSOZZHK-DOPDSADYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
- 108010002913 Asialoglycoproteins Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 101100284398 Bos taurus BoLA-DQB gene Proteins 0.000 description 1
- 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 description 1
- 241000702371 Enterobacteria phage f1 Species 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 102100036241 HLA class II histocompatibility antigen, DQ beta 1 chain Human genes 0.000 description 1
- 102100040505 HLA class II histocompatibility antigen, DR alpha chain Human genes 0.000 description 1
- 108010041384 HLA-DPA antigen Proteins 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 108010047762 HLA-DQ8 antigen Proteins 0.000 description 1
- 108010086786 HLA-DQA1 antigen Proteins 0.000 description 1
- 108010067148 HLA-DQbeta antigen Proteins 0.000 description 1
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 description 1
- 108010093013 HLA-DR1 Antigen Proteins 0.000 description 1
- 108010064885 HLA-DR3 Antigen Proteins 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000957437 Homo sapiens Mitochondrial carnitine/acylcarnitine carrier protein Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108700001097 Insect Genes Proteins 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102100038738 Mitochondrial carnitine/acylcarnitine carrier protein Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 241001377010 Pila Species 0.000 description 1
- 101710193132 Pre-hexon-linking protein VIII Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000012769 bulk production Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013632 covalent dimer Substances 0.000 description 1
- 150000001944 cysteine derivatives Chemical class 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000005014 ectopic expression Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 108010087558 pectate lyase Proteins 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000003094 perturbing effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 230000010464 virion assembly Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30572810P | 2010-02-18 | 2010-02-18 | |
| GBGB1002730.8A GB201002730D0 (en) | 2010-02-18 | 2010-02-18 | Product |
| US31657610P | 2010-03-23 | 2010-03-23 | |
| PCT/GB2011/050325 WO2011101681A2 (en) | 2010-02-18 | 2011-02-18 | Disulphide bond-stabilized functional soluble mhc class ii heterodimers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2536746T3 true DK2536746T3 (en) | 2016-05-30 |
Family
ID=42113985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11730044.2T DK2536746T3 (en) | 2010-02-18 | 2011-02-18 | Disulphide-bond stabilized functional soluble MHC class II heterodimeric |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8828379B2 (https=) |
| EP (1) | EP2536746B1 (https=) |
| JP (1) | JP5537675B2 (https=) |
| KR (1) | KR101647176B1 (https=) |
| CN (1) | CN102947330B (https=) |
| AU (1) | AU2011217027B2 (https=) |
| CA (1) | CA2789492C (https=) |
| CY (1) | CY1117697T1 (https=) |
| DK (1) | DK2536746T3 (https=) |
| ES (1) | ES2572388T3 (https=) |
| GB (1) | GB201002730D0 (https=) |
| HR (1) | HRP20160475T1 (https=) |
| HU (1) | HUE027952T2 (https=) |
| PL (1) | PL2536746T3 (https=) |
| RS (1) | RS54744B1 (https=) |
| RU (1) | RU2604813C2 (https=) |
| SI (1) | SI2536746T1 (https=) |
| WO (1) | WO2011101681A2 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10787701B2 (en) | 2010-04-05 | 2020-09-29 | Prognosys Biosciences, Inc. | Spatially encoded biological assays |
| ES3011307T3 (en) | 2012-02-23 | 2025-04-07 | Juno Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
| EP4592400A3 (en) | 2012-10-17 | 2025-10-29 | 10x Genomics Sweden AB | Methods and product for optimising localised or spatial detection of gene expression in a tissue sample |
| GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
| JP6748061B2 (ja) * | 2014-07-09 | 2020-08-26 | ルピン・リミテッド | 二重シストロン細菌発現システム |
| US11059880B2 (en) | 2015-06-30 | 2021-07-13 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Redirected cells with MHC chimeric receptors and methods of use in immunotherapy |
| US12577289B2 (en) | 2015-06-30 | 2026-03-17 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Surrogate co-receptors for t cells and methods of use |
| MX2018004875A (es) | 2015-10-22 | 2018-08-01 | Juno Therapeutics Gmbh | Metodos para cultivar celulas y kits y aparatos para ello. |
| EP3365453A2 (en) | 2015-10-22 | 2018-08-29 | Juno Therapeutics GmbH | Methods, kits, agents and apparatuses for transduction |
| US10294454B2 (en) | 2016-08-24 | 2019-05-21 | General Electric Company | Methods and kits for cell activation |
| US20180127481A1 (en) * | 2016-11-09 | 2018-05-10 | Uti Limited Partnership | RECOMBINANT pMHC CLASS II MOLECULES |
| JP7339160B2 (ja) | 2017-04-27 | 2023-09-05 | ジュノ セラピューティクス ゲーエムベーハー | オリゴマー粒子試薬およびその使用方法 |
| DE102018122546B3 (de) | 2018-09-14 | 2019-12-05 | Immatics Biotechnologies Gmbh | Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden |
| EP4345453B1 (en) * | 2018-09-28 | 2025-11-12 | 10X Genomics, Inc. | High throughput epitope identification and t cell receptor specificity determination using loadable detection molecules |
| SG11202104355SA (en) | 2018-10-31 | 2021-05-28 | Juno Therapeutics Gmbh | Methods for selection and stimulation of cells and apparatus for same |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| EP3719033A1 (en) * | 2019-04-02 | 2020-10-07 | imusyn GmbH & Co. KG | Stabilized mhc i |
| WO2021035049A1 (en) * | 2019-08-21 | 2021-02-25 | Uti Limited Partnership | Improved recombinant pmhc molecules |
| EP4028412A2 (en) * | 2019-09-13 | 2022-07-20 | The Regents of The University of California | Systems and methods for the preparation of peptide-mhc-i complexes with native glycan modifications |
| US20220409732A1 (en) * | 2019-12-02 | 2022-12-29 | Regeneron Pharmaceuticals, Inc. | Peptide-mhc ii protein constructs and uses thereof |
| TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
| TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
| DE102020109447A1 (de) | 2020-04-03 | 2021-10-07 | Jacobs University Bremen Ggmbh | Synthetisches mhc-klasse-ii-protein |
| US12534510B2 (en) | 2020-04-16 | 2026-01-27 | The Regents Of The University Of California | Peptide-receptive MHC-I complex compositions and methods |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| CN118813436A (zh) * | 2023-07-24 | 2024-10-22 | 佳吾益(北京)科技有限公司 | 展示单mhc等位基因功能蛋白的工程化细胞 |
| CN119220425A (zh) * | 2023-07-28 | 2024-12-31 | 佳吾益(北京)科技有限公司 | 发现mhc新抗原肽表位的工程化细胞 |
| WO2025137580A1 (en) * | 2023-12-22 | 2025-06-26 | Antiger Therapeutics, Inc. | Class ii hla with inter-chain disulfide bond |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990010457A1 (en) | 1989-03-14 | 1990-09-20 | New York University | Method of treating hiv infections using immunotoxins |
| JP2000516470A (ja) * | 1996-08-16 | 2000-12-12 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 可溶性一価および多価ｍｈｃクラスｉｉ融合タンパク質およびそれらの使用 |
| CA2302779C (en) * | 1997-09-16 | 2010-02-02 | Oregon Health Sciences University | Recombinant mhc molecules useful for manipulation of antigen-specific t-cells |
| WO1999060120A2 (en) * | 1998-05-19 | 1999-11-25 | Avidex Limited | Soluble t cell receptor |
| RU2303264C2 (ru) * | 2001-02-19 | 2007-07-20 | Мерк Патент Гмбх | Способ идентификации эпитопов т-клеток и его применение для получения молекул со сниженной иммуногенностью |
| GB2392158B (en) * | 2002-08-21 | 2005-02-16 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof |
| US8377447B2 (en) * | 2003-09-05 | 2013-02-19 | Oregon Health & Science University | Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells |
| CA2638892A1 (en) | 2005-03-18 | 2006-09-28 | Oregon Health & Science University | Recombinant mhc molecules useful for manipulation of antigen-specific t cells |
| ES2709176T3 (es) | 2006-08-11 | 2019-04-15 | Life Sciences Res Partners Vzw | Péptidos inmunogénicos y su uso en trastornos inmunitarios |
| JP5154564B2 (ja) * | 2006-12-01 | 2013-02-27 | カール・ツァイス・エスエムティー・ゲーエムベーハー | 像収差を低減するための交換可能で操作可能な補正構成を有する光学システム |
| ES2445152T3 (es) | 2007-08-20 | 2014-02-28 | Nextera As | Presentación en fagos de pVII |
-
2010
- 2010-02-18 GB GBGB1002730.8A patent/GB201002730D0/en not_active Ceased
-
2011
- 2011-02-18 AU AU2011217027A patent/AU2011217027B2/en active Active
- 2011-02-18 WO PCT/GB2011/050325 patent/WO2011101681A2/en not_active Ceased
- 2011-02-18 KR KR1020127024287A patent/KR101647176B1/ko active Active
- 2011-02-18 DK DK11730044.2T patent/DK2536746T3/en active
- 2011-02-18 HR HRP20160475TT patent/HRP20160475T1/hr unknown
- 2011-02-18 RS RS20160323A patent/RS54744B1/sr unknown
- 2011-02-18 PL PL11730044T patent/PL2536746T3/pl unknown
- 2011-02-18 ES ES11730044T patent/ES2572388T3/es active Active
- 2011-02-18 EP EP11730044.2A patent/EP2536746B1/en active Active
- 2011-02-18 RU RU2012138302/10A patent/RU2604813C2/ru active
- 2011-02-18 US US13/579,887 patent/US8828379B2/en active Active
- 2011-02-18 CA CA2789492A patent/CA2789492C/en active Active
- 2011-02-18 SI SI201130815A patent/SI2536746T1/sl unknown
- 2011-02-18 JP JP2012553409A patent/JP5537675B2/ja active Active
- 2011-02-18 CN CN201180011237.4A patent/CN102947330B/zh active Active
- 2011-02-18 HU HUE11730044A patent/HUE027952T2/en unknown
-
2014
- 2014-07-14 US US14/331,014 patent/US9056920B2/en active Active
-
2016
- 2016-05-11 CY CY20161100397T patent/CY1117697T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130009782A (ko) | 2013-01-23 |
| GB201002730D0 (en) | 2010-04-07 |
| WO2011101681A2 (en) | 2011-08-25 |
| JP5537675B2 (ja) | 2014-07-02 |
| AU2011217027B2 (en) | 2015-02-05 |
| CA2789492C (en) | 2017-04-18 |
| ES2572388T3 (es) | 2016-05-31 |
| KR101647176B1 (ko) | 2016-08-09 |
| US8828379B2 (en) | 2014-09-09 |
| PL2536746T3 (pl) | 2016-08-31 |
| RS54744B1 (sr) | 2016-10-31 |
| SI2536746T1 (sl) | 2016-09-30 |
| RU2012138302A (ru) | 2014-03-27 |
| RU2604813C2 (ru) | 2016-12-10 |
| WO2011101681A3 (en) | 2011-12-08 |
| US20130171668A1 (en) | 2013-07-04 |
| US9056920B2 (en) | 2015-06-16 |
| JP2013519721A (ja) | 2013-05-30 |
| HUE027952T2 (en) | 2016-11-28 |
| EP2536746A2 (en) | 2012-12-26 |
| US20140349315A1 (en) | 2014-11-27 |
| HRP20160475T1 (hr) | 2016-06-03 |
| CN102947330B (zh) | 2015-09-16 |
| CY1117697T1 (el) | 2017-05-17 |
| CA2789492A1 (en) | 2011-08-25 |
| AU2011217027A1 (en) | 2012-09-06 |
| EP2536746B1 (en) | 2016-04-20 |
| CN102947330A (zh) | 2013-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2536746T3 (en) | Disulphide-bond stabilized functional soluble MHC class II heterodimeric | |
| EP3850363B1 (en) | Method for high throughput peptide-mhc affinity screening for tcr ligands by stabilised, peptide-free mhc complexes | |
| EP1882700B1 (en) | Biotinylated MHC complexes and their uses | |
| US20240294601A1 (en) | Peptide deficient-mhc class i/chaperone compositions and methods | |
| Landais et al. | New design of MHC class II tetramers to accommodate fundamental principles of antigen presentation | |
| US20240262885A1 (en) | Systems and methods for the preparation of peptide-mhc-i complexes with native glycan modifications | |
| US20210179668A1 (en) | Novel mammalian expressed human immunodeficiency virus envelope protein antigens | |
| EP3994161A1 (en) | Peptide-mhc complexes | |
| BR112021007530A2 (pt) | Polipeptídeo que tem uma estrutura helicoidal tripla, proteína de fusão, método para gerar um polipeptídeo que tem uma estrutura helicoidal tripla, composição, método para reduzir a afinidade de ligação de um polipeptídeo que tem uma estrutura helicoidal tripla para o domínio fc de imunoglobulina, e polinucleotídeo | |
| US11814420B2 (en) | Peptide deficient-MHC class I/chaperone compositions and methods | |
| US20240076356A1 (en) | Display of peptide-mhc (pmhc) on multimeric protein scaffolds and uses thereof | |
| HK1177939B (en) | Disulphide bond-stabilized functional soluble mhc class ii heterodimers | |
| Fortin et al. | MMTV superantigens coerce an unconventional topology between the TCR and MHC class II | |
| Sharma et al. | Refolding of HLA-B27 heavy chains in the absence of β2m yields stable high molecular weight (HMW) protein forms displaying native-like as well as non-native-like conformational features: Implications for autoimmune disease |